Abstract: The present disclosure relates to an isolated antibody, or antigen binding fragment thereof, which specifically binds to an extracellular domain of cd300f, wherein the antibody, or antigen binding fragment thereof, comprises a heavy chain variable region which comprises: (a) an amino acid sequence that is at least 70% identical to the amino acid sequence represented by seq id no: 1; and/or (b) a complementarity determining region 1 (cdr1) that comprises the amino acid sequence represented by seq id no: 2, a complementarity determining region 2 (cdr2) that comprises an amino acid sequence that is represented by seq id no: 3, and/or a complementarity determining region 3 (cdr3) that comprises an amino acid sequence that is represented by seq id no: 4, compositions comprising the antibody, antigen binding fragment thereof, and uses for therapy.

Abstract: The present disclosure relates to an immunoconjugate including an antibody, or antigen binding fragment thereof, that specifically binds to CD300f, linked to at least one cytotoxic agent, and to compositions including the immunoconjugate, and use of the immunoconjugate for depleting haematopoietic stem and progenitor cells, for preparing a subject haematopoietic stem cell transplantation, and for the treatment of CD300f associated conditions.

Abstract: The present disclosure relates to proteins that bind to CD83 and uses thereof, for example, in therapy, prophylaxis, diagnosis, or prognosis.

Abstract: The present disclosure relates to proteins that bind to CD83 and uses thereof, for example, in therapy, prophylaxis, diagnosis or prognosis.

Abstract: The present disclosure relates to proteins that bind to CD83 and uses thereof, for example, in therapy, prophylaxis, diagnosis or prognosis.

Abstract: The present disclosure relates to proteins that bind to CD83 and uses thereof, for example, in therapy, prophylaxis, diagnosis, or prognosis.

Abstract: An isolated or recombinant CD83 binding protein may include an antigen binding domain, wherein the antigen binding domain binds specifically to CD83 or a cell expressing CD83.